Renowned growth consultants Frost & Sullivan have awarded this year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications. For example, Capsulution developed innovative drug delivery solutions for pharmaceutically active compounds. Wrapped in tiny nano-capsules these will be delivered safely to the desired location of action in the human body.

“We are very delighted about the award since it demonstrates that we have considerably advanced our vision to develop innovative and highly specialized products on the basis of the LBL-Technology®,” said Alexander Herrmann, Chief Financial Officer of Capsulution NanoScience AG.

Proprietary LBL Technology®

Capsulution’s products are based around the proprietary LBL-Technology® (Layer-By-Layer) – a method of producing polymeric nano-capsules. This encapsulation system is highly versatile. Various polymers can be applied to encapsulate pharmaceutical as well as other chemical compounds. Additionally, the exterior of the capsule may be functionalised through the addition of targeting molecules such as monoclonal antibodies.

Broad field of applications

Capsulution’s LBL-Technology® platform will soon be used for a wide range of applications. LBL-Solv is a means of drug reformulation, where water insoluble active compounds are nanoencapsulated to increase their bioavailability. In addition, LBL-Intra is an application specific to intracellular drug delivery. The capsules may also be applied to improve the function of drug-releasing implants.

Nano-diagnostics as a new application

Capsulution is also working on the development and expansion of its nano-diagnostics capabilities, mostly in cooperation with prominent industry partners. Equipped with a variety of functional groups attached the LBL capsules facilitate the detection of DNA or the diagnosis of diseases. A first such product is already marketed in the US since 2005 – others are currently under development.

Further information:
Capsulution NanoScience AG
Alexander Herrmann (CFO)
Volmerstr. 7b
D- 12489 Berlin, Germany
Tel.: +49-(0)30-63923627
Fax.: +49-(0)30-63923601
Web: www.capsulution.com
eMail: alexander.herrmann@capsulution.com